查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球人源化小鼠和大鼠模型市场（按类型、最终用户、应用和地区划分）—预测至2030年
市场调查报告书
商品编码
1715158

全球人源化小鼠和大鼠模型市场（按类型、最终用户、应用和地区划分）—预测至2030年

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 255 Pages | 订单完成后即时交付

价格

预计全球人源化小鼠和大鼠模型市场规模将从 2025 年的 2.762 亿美元成长到 2030 年的 4.098 亿美元，复合年增长率高达 8.2%。

由于製药和生物製药公司不断增加研发投入，市场正以高复合年增长率强劲成长。随着研发管道的扩大以及罕见疾病和孤儿药倡议的发展，对外包分析测试的需求也不断增长。此外，内部药物开发的高成本也助长了这一趋势。由于技术进步、新药研发技术、专利到期以及最终用户对专业测试服务的需求不断增加，该行业的公司预计将经历健康的成长机会。

研究范围
调查年份 2024-2030
基准年 2024
预测期 2024-2030
对价单位 金额（百万美元）
部分 按类型、按最终用户、按应用程式、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

根据类型，人源化小鼠和大鼠模型市场分为人源化小鼠模型和人源化大鼠模型。预计到 2024 年，人源化小鼠模型将在市场收益方面占据最大份额。此外，预计该细分市场在整个预测期内将以最快的复合年增长率成长。对基于细胞的人源化小鼠模型的需求不断增长，促进了这一领域的成长。这些模型有多种应用，包括潜在新药的安全性和有效性分析以及免疫肿瘤学、感染疾病和移植物抗宿主疾病的纵向研究。

人源化小鼠和大鼠模型市场依应用分为肿瘤学、免疫学/感染疾病、神经科学、造血、毒理学等领域。就销售额而言，免疫学和感染疾病部门是我们第二大部门。小鼠模型用于免疫学和发炎研究，因为它们有助于评估实验结果的生理相关性。小鼠模型允许随机改变小鼠基因组或在特定区域改变，从而可以详细研究免疫学过程。

根据最终用户，市场细分为製药和生物技术公司、CRO/CDMO 以及学术和研究机构。 2024 年，製药和生物技术公司将主导这一领域。由于创新药物开发支出的增加和对个人化医疗的偏好日益增长，製药和生物技术公司占据人源化小鼠和大鼠模型市场的最大份额。然而，由于越来越多的製药和生物技术公司将药物开发的临床前试验和研究活动委託这个最终用户部门，预计 CRO 和 CDMO 部门将在预测期内实现最高成长。

市场依地区分为北美、欧洲、亚太、拉丁美洲及中东及非洲。 2024 年，北美占据了人源化小鼠和大鼠模型市场的主导地位，预计在预测期内将继续占据主导地位。在主要参与企业的推动下，美国引领北美市场。该市场的巨大份额主要得益于生命科学研究资金的增加以及对 mAb 和生物相似药研究的不断增长。此外，癌症发生率的上升也有望支持市场的成长。

本报告研究了全球人源化小鼠和大鼠模型市场，并对市场类型、最终用户、应用、地区和公司概况进行了深入分析。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章市场概述

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/中断
  • 定价分析
  • 供应链分析
  • 价值链分析
  • 生态系分析
  • 投资金筹措场景
  • 技术分析
  • 专利分析
  • 贸易分析
  • 2025-2026 年重要会议与活动
  • 监管状况
  • 波特五力分析
  • 主要相关人员和采购标准
  • 人工智慧对人源化小鼠和大鼠模型市场的影响

6. 人源化小鼠和大鼠模型市场（按类型）

  • 介绍
  • 人源化小鼠模型
  • 人源化大鼠模型

7. 人源化小鼠和大鼠模型市场（依最终用户划分）

  • 介绍
  • 製药和生物技术公司
  • CRO 和 CDMO
  • 学术研究所

第八章人源化小鼠和大鼠模型市场（按应用）

  • 介绍
  • 肿瘤学
  • 免疫学和感染疾病
  • 神经科学
  • 毒理学
  • 造血
  • 其他的

9. 人源化小鼠和大鼠模型市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他的
  • 拉丁美洲
    • 随着製药和生物技术公司日益突出，市场不断扩大
    • 拉丁美洲宏观经济展望
  • 中东
    • 支持市场成长的国家医药市场的成长
    • 中东宏观经济展望
  • 非洲
    • 製药业的蓬勃发展将支持市场成长
    • 非洲宏观经济展望

第十章 竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 2020-2024年收益分析
  • 2024年市场占有率分析
  • 估值和财务指标
  • 品牌/产品比较
  • 公司估值矩阵：2024 年主要参与企业
  • 公司估值矩阵：Start-Ups/中小企业，2024 年
  • 竞争场景

第十一章 公司简介

  • 主要参与企业
    • CHARLES RIVER LABORATORIES
    • THE JACKSON LABORATORY
    • INOTIV
    • GENOWAY
    • TACONIC BIOSCIENCES, INC.
    • JSR CORPORATION
    • CHAMPIONS ONCOLOGY, INC.
    • JANVIER LABS
    • VITALSTAR BIOTECHNOLOGY
    • INGENIOUS TARGETING LABORATORY
    • HARBOUR BIOMED
    • ONCODESIGN SERVICES
    • PHARMATEST SERVICES
  • 其他公司
    • OZGENE PTY LTD.
    • CLEA JAPAN, INC.
    • ALTOGEN LABS
    • REACTION BIOLOGY
    • TRANSCURE BIOSERVICES
    • CYAGEN
    • ARAGEN LIFE SCIENCES LTD.
    • BIOCYTOGEN
    • GEMPHARMATECH

第十二章 附录

Product Code: BT 4938

The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%. The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD million)
SegmentsType, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

"Humanized mouse model segment dominated the type segment in 2024"

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment's growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease.

"The immunology & infectious diseases segment accounted for the second largest share of the market in 2024"

The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.

"Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment.

"US to record the highest CAGR during the forecast period"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth.

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
  • By Designation: C-level Executives - 45%, Directors - 30%, and Others - 25%
  • By Region: North America - 45%, Europe - 30%, Asia Pacific - 20%, Latin America - 3% and Middle East & Africa - 2%

Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market.

Research Coverage:

Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth.
  • Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market.
  • Market Development: Comprehensive information about lucrative markets-the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 MARKET SEGMENTATION AND REGIONS COVERED
    • 1.4.2 YEARS CONSIDERED
    • 1.4.3 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Objectives of secondary research
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Objectives of primary research
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.2 SEGMENTAL MARKET ESTIMATION
  • 2.3 GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
  • 4.2 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY, 2024
  • 4.3 HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY
  • 4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising use of humanized models in drug discovery research
      • 5.2.1.2 Emerging preclinical applications of humanized mouse models
      • 5.2.1.3 Government-funded initiatives for cancer research
      • 5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industry
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Introduction of FDA Modernization Act 2.0/3.0
      • 5.2.2.2 Stringent regulatory compliance for ethical use of animal models
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing preference for humanized PDX models
      • 5.2.3.2 Emergence of CRISPR in biomedical research
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Alternative methods for animal testing
      • 5.2.4.2 Limitations of humanized mouse models
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 CRISPR-Cas9
      • 5.9.1.2 Tissue engineering
      • 5.9.1.3 In vivo imaging
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 3D cell culture
      • 5.9.2.2 Organs-on-Chips
      • 5.9.2.3 Biomarker discovery
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Proteomics
      • 5.9.3.2 Microfluidics
      • 5.9.3.3 Regenerative medicine
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.13 REGULATORY LANDSCAPE
    • 5.13.1 REGULATORY FRAMEWORK
    • 5.13.2 NORTH AMERICA
    • 5.13.3 EUROPE
    • 5.13.4 ASIA PACIFIC
      • 5.13.4.1 China
      • 5.13.4.2 Japan
      • 5.13.4.3 India
      • 5.13.4.4 Australia
    • 5.13.5 LATIN AMERICA
    • 5.13.6 MIDDLE EAST & AFRICA
    • 5.13.7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14 PORTER'S FIVE FORCES ANALYSIS
    • 5.14.1 THREAT OF NEW ENTRANTS
    • 5.14.2 THREAT OF SUBSTITUTES
    • 5.14.3 BARGAINING POWER OF SUPPLIERS
    • 5.14.4 BARGAINING POWER OF BUYERS
    • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.15.2 KEY BUYING CRITERIA, BY END USER
  • 5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET
    • 5.16.1 INTRODUCTION
    • 5.16.2 MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS
    • 5.16.3 AI USE CASES
    • 5.16.4 KEY COMPANIES IMPLEMENTING AI
    • 5.16.5 FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 HUMANIZED MOUSE MODELS
    • 6.2.1 GENETIC HUMANIZED MOUSE MODELS
      • 6.2.1.1 Advancements in genetical engineering technologies to drive market
    • 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
      • 6.2.2.1 CD34 humanized mouse models
        • 6.2.2.1.1 Rising demand for stem cell therapy to propel market
      • 6.2.2.2 PBMC humanized mouse models
        • 6.2.2.2.1 Growing prevalence of infectious diseases to boost demand
      • 6.2.2.3 BLT humanized mouse models
        • 6.2.2.3.1 Surge in HIV cases to drive market
  • 6.3 HUMANIZED RAT MODELS
    • 6.3.1 PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

  • 7.1 INTRODUCTION
  • 7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 7.2.1 GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH
  • 7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
    • 7.3.1 OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
  • 7.4 ACADEMIC & RESEARCH INSTITUTES
    • 7.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    • 8.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET
  • 8.3 IMMUNOLOGY AND INFECTIOUS DISEASES
    • 8.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
  • 8.4 NEUROSCIENCE
    • 8.4.1 RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET
  • 8.5 TOXICOLOGY
    • 8.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
  • 8.6 HEMATOPOIESIS
    • 8.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
  • 8.7 OTHER APPLICATIONS

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
    • 9.2.2 US
      • 9.2.2.1 Growing research initiatives on mAbs and biosimilars to drive market
    • 9.2.3 CANADA
      • 9.2.3.1 Government initiatives on stem cell research to drive market
  • 9.3 EUROPE
    • 9.3.1 MACROECONOMIC OUTLOOK OF EUROPE
    • 9.3.2 GERMANY
      • 9.3.2.1 Rising pharmaceutical R&D expenditure to drive market
    • 9.3.3 UK
      • 9.3.3.1 Growing investments in cancer research to drive market
    • 9.3.4 FRANCE
      • 9.3.4.1 Rising initiatives for genomics research to support market growth
    • 9.3.5 ITALY
      • 9.3.5.1 Robust pharmaceutical production to fuel market
    • 9.3.6 SPAIN
      • 9.3.6.1 Rising growth in biotech industry to drive market
    • 9.3.7 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
    • 9.4.2 CHINA
      • 9.4.2.1 High growth in pharmaceutical industry to drive market
    • 9.4.3 JAPAN
      • 9.4.3.1 Growing research collaborations among pharmaceutical companies to drive market
    • 9.4.4 INDIA
      • 9.4.4.1 Growth in biotech industry to drive market
    • 9.4.5 SOUTH KOREA
      • 9.4.5.1 Rising government-funded investments for pharmaceutical R&D to drive market
    • 9.4.6 AUSTRALIA
      • 9.4.6.1 Rising biomedical research projects to drive market
    • 9.4.7 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
    • 9.5.2 MACROECONOMIC OUTLOOK OF LATIN AMERICA
  • 9.6 MIDDLE EAST
    • 9.6.1 GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH
    • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 9.7 AFRICA
    • 9.7.1 GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
    • 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET
  • 10.3 REVENUE ANALYSIS, 2020-2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
    • 10.4.1 HUMANIZED MOUSE AND RAT MODEL MARKET
  • 10.5 COMPANY VALUATION AND FINANCIAL METRICS
    • 10.5.1 FINANCIAL METRICS
  • 10.6 BRAND/PRODUCT COMPARISON
  • 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 10.7.1 STARS
    • 10.7.2 EMERGING LEADERS
    • 10.7.3 PERVASIVE PLAYERS
    • 10.7.4 PARTICIPANTS
    • 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 10.7.5.1 Company footprint
      • 10.7.5.2 Region footprint
      • 10.7.5.3 Type footprint
      • 10.7.5.4 Application footprint
  • 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 10.8.1 PROGRESSIVE COMPANIES
    • 10.8.2 RESPONSIVE COMPANIES
    • 10.8.3 DYNAMIC COMPANIES
    • 10.8.4 STARTING BLOCKS
    • 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
      • 10.8.5.1 Detailed list of key startups/SMEs
      • 10.8.5.2 Competitive benchmarking of key startups/SMEs
  • 10.9 COMPETITIVE SCENARIO
    • 10.9.1 PRODUCT LAUNCHES & APPROVALS
    • 10.9.2 DEALS
    • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
    • 11.1.1 CHARLES RIVER LABORATORIES
      • 11.1.1.1 Business overview
      • 11.1.1.2 Products offered
      • 11.1.1.3 Recent developments
        • 11.1.1.3.1 Deals
        • 11.1.1.3.2 Other developments
      • 11.1.1.4 MnM view
        • 11.1.1.4.1 Key strengths
        • 11.1.1.4.2 Strategic choices
        • 11.1.1.4.3 Weaknesses and competitive threats
    • 11.1.2 THE JACKSON LABORATORY
      • 11.1.2.1 Business overview
      • 11.1.2.2 Products offered
      • 11.1.2.3 Recent developments
        • 11.1.2.3.1 Deals
      • 11.1.2.4 MnM view
        • 11.1.2.4.1 Key strengths
        • 11.1.2.4.2 Strategic choices
        • 11.1.2.4.3 Weaknesses and competitive threats
    • 11.1.3 INOTIV
      • 11.1.3.1 Business overview
      • 11.1.3.2 Products offered
      • 11.1.3.3 Recent developments
        • 11.1.3.3.1 Deals
      • 11.1.3.4 MnM view
        • 11.1.3.4.1 Key strengths
        • 11.1.3.4.2 Strategic choices
        • 11.1.3.4.3 Weaknesses and competitive threats
    • 11.1.4 GENOWAY
      • 11.1.4.1 Business overview
      • 11.1.4.2 Products offered
      • 11.1.4.3 Recent developments
        • 11.1.4.3.1 Other developments
      • 11.1.4.4 MnM view
        • 11.1.4.4.1 Key strengths
        • 11.1.4.4.2 Strategic choices
        • 11.1.4.4.3 Weaknesses and competitive threats
    • 11.1.5 TACONIC BIOSCIENCES, INC.
      • 11.1.5.1 Business overview
      • 11.1.5.2 Products offered
      • 11.1.5.3 Recent developments
        • 11.1.5.3.1 Product launches
        • 11.1.5.3.2 Expansions
    • 11.1.6 JSR CORPORATION
      • 11.1.6.1 Business overview
      • 11.1.6.2 Products offered
      • 11.1.6.3 Recent developments
        • 11.1.6.3.1 Deals
        • 11.1.6.3.2 Expansions
    • 11.1.7 CHAMPIONS ONCOLOGY, INC.
      • 11.1.7.1 Business overview
      • 11.1.7.2 Products offered
    • 11.1.8 JANVIER LABS
      • 11.1.8.1 Business overview
      • 11.1.8.2 Products offered
      • 11.1.8.3 Recent developments
        • 11.1.8.3.1 Deals
    • 11.1.9 VITALSTAR BIOTECHNOLOGY
      • 11.1.9.1 Business overview
      • 11.1.9.2 Products offered
    • 11.1.10 INGENIOUS TARGETING LABORATORY
      • 11.1.10.1 Business overview
      • 11.1.10.2 Products offered
    • 11.1.11 HARBOUR BIOMED
      • 11.1.11.1 Business overview
      • 11.1.11.2 Products offered
      • 11.1.11.3 Recent developments
        • 11.1.11.3.1 Deals
    • 11.1.12 ONCODESIGN SERVICES
      • 11.1.12.1 Business overview
      • 11.1.12.2 Products offered
    • 11.1.13 PHARMATEST SERVICES
      • 11.1.13.1 Business overview
      • 11.1.13.2 Products offered
  • 11.2 OTHER PLAYERS
    • 11.2.1 OZGENE PTY LTD.
    • 11.2.2 CLEA JAPAN, INC.
    • 11.2.3 ALTOGEN LABS
    • 11.2.4 REACTION BIOLOGY
    • 11.2.5 TRANSCURE BIOSERVICES
    • 11.2.6 CYAGEN
    • 11.2.7 ARAGEN LIFE SCIENCES LTD.
    • 11.2.8 BIOCYTOGEN
    • 11.2.9 GEMPHARMATECH

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 HUMANIZED MOUSE AND RAT MODEL MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
  • TABLE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RISK ANALYSIS
  • TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 NUMBER OF R&D PRODUCTS, BY INDICATION (2024)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD MILLION)
  • TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022-2024 (USD)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS (HUMANIZED MOUSE MODELS), BY REGION, 2022-2024 (USD)
  • TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021-2025
  • TABLE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021-2024
  • TABLE 12 IMPORT DATA FOR LABORATORY MOUSE
  • TABLE 13 EXPORT DATA FOR LABORATORY MOUSE
  • TABLE 14 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 21 KEY BUYING CRITERIA, BY END USER
  • TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • TABLE 24 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 25 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 30 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 34 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 35 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 CD34 HUMANIZED MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 43 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 HUMANIZED RAT MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 55 USE OF HUMANIZED MICE MODELS IN DEVELOPED AND TESTED VACCINES
  • TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 97 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 100 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA
  • TABLE 101 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 102 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 103 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 104 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 105 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 106 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 107 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 108 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 109 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 110 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 111 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 113 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 114 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 115 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 117 KEY MACROECONOMIC INDICATORS OF EUROPE
  • TABLE 118 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 119 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 120 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 121 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 122 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 123 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 124 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 125 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 126 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 127 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 128 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 129 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 130 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 131 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 132 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 133 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 134 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 135 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 137 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 138 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 139 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 140 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 141 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 142 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 143 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 144 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 145 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 146 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 147 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 154 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC
  • TABLE 155 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 156 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 157 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 158 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 159 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 160 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 161 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 162 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 163 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 164 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 165 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 166 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 167 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 168 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 169 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 170 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 171 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 172 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 173 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 174 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 175 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 AUSTRALIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 177 AUSTRALIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 178 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 179 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 180 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 181 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 182 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 183 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 184 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 185 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 186 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 188 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 189 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 190 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA
  • TABLE 191 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 192 MIDDLE EAST: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 MIDDLE EAST: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 194 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 195 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 196 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST
  • TABLE 197 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 199 AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 200 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 201 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 202 KEY MACROECONOMIC INDICATORS OF AFRICA
  • TABLE 203 STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2021-2024
  • TABLE 204 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION
  • TABLE 205 HUMANIZED MOUSE AND RAT MODEL MARKET: REGION FOOTPRINT
  • TABLE 206 HUMANIZED MOUSE AND RAT MODEL MARKET: TYPE FOOTPRINT
  • TABLE 207 HUMANIZED MOUSE AND RAT MODEL MARKET: APPLICATION FOOTPRINT
  • TABLE 208 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STARTUPS/SMES
  • TABLE 209 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
  • TABLE 210 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
  • TABLE 211 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 212 HUMANIZED MOUSE AND RAT MODEL MARKET: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 213 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 214 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED
  • TABLE 215 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 216 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 217 THE JACKSON LABORATORY: COMPANY OVERVIEW
  • TABLE 218 THE JACKSON LABORATORY: PRODUCTS OFFERED
  • TABLE 219 THE JACKSON LABORATORY: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 220 INOTIV: COMPANY OVERVIEW
  • TABLE 221 INOTIV: PRODUCTS OFFERED
  • TABLE 222 INOTIV: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 223 GENOWAY: COMPANY OVERVIEW
  • TABLE 224 GENOWAY: PRODUCTS OFFERED
  • TABLE 225 GENOWAY: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 226 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 227 TACONIC BIOSCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 228 TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES, JANUARY 2021-JANUARY 2025
  • TABLE 229 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025
  • TABLE 230 JSR CORPORATION: COMPANY OVERVIEW
  • TABLE 231 JSR CORPORATION: PRODUCTS OFFERED
  • TABLE 232 JSR CORPORATION: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 233 JSR CORPORATION: EXPANSIONS, JANUARY 2021-JANUARY 2025
  • TABLE 234 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 235 CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED
  • TABLE 236 JANVIER LABS: COMPANY OVERVIEW
  • TABLE 237 JANVIER LABS: PRODUCTS OFFERED
  • TABLE 238 JANVIER LABS: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 239 VITALSTAR BIOTECHNOLOGY: COMPANY OVERVIEW
  • TABLE 240 VITALSTAR BIOTECHNOLOGY: PRODUCTS OFFERED
  • TABLE 241 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW
  • TABLE 242 INGENIOUS TARGETING LABORATORY: PRODUCTS OFFERED
  • TABLE 243 HARBOUR BIOMED: COMPANY OVERVIEW
  • TABLE 244 HARBOUR BIOMED: PRODUCTS OFFERED
  • TABLE 245 HARBOUR BIOMED: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 246 ONCODESIGN SERVICES: COMPANY OVERVIEW
  • TABLE 247 ONCODESIGN SERVICES: PRODUCTS OFFERED
  • TABLE 248 PHARMATEST SERVICES: COMPANY OVERVIEW
  • TABLE 249 PHARMATEST SERVICES: PRODUCTS OFFERED
  • TABLE 250 OZGENE PTY LTD.: COMPANY OVERVIEW
  • TABLE 251 CLEA JAPAN, INC.: COMPANY OVERVIEW
  • TABLE 252 ALTOGEN LABS: COMPANY OVERVIEW
  • TABLE 253 REACTION BIOLOGY: COMPANY OVERVIEW
  • TABLE 254 TRANSCURE BIOSERVICES: COMPANY OVERVIEW
  • TABLE 255 CYAGEN: COMPANY OVERVIEW
  • TABLE 256 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
  • TABLE 257 BIOCYTOGEN: COMPANY OVERVIEW
  • TABLE 258 GEMPHARMATECH: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 HUMANIZED MOUSE AND RAT MODEL MARKET SEGMENTATION AND REGIONS CONSIDERED
  • FIGURE 2 HUMANIZED MOUSE AND RAT MODEL MARKET: YEARS CONSIDERED
  • FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
  • FIGURE 5 GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET SIZE ESTIMATION, 2024
  • FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
  • FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024
  • FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS, 2025-2030
  • FIGURE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: DATA TRIANGULATION
  • FIGURE 12 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2025-2030
  • FIGURE 16 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET
  • FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN US IN 2024
  • FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024
  • FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 NUMBER OF CLINICAL TRIALS REGISTERED FOR CANCER IMMUNOTHERAPIES, 2020-2024
  • FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 23 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
  • FIGURE 24 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022-2024 (USD)
  • FIGURE 25 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022-2024 (USD)
  • FIGURE 26 HUMANIZED MOUSE AND RAT MODEL MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 HUMANIZED MOUSE AND RAT MODEL MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 HUMANIZED MOUSE AND RAT MODEL MARKET ECOSYSTEM
  • FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2021-2025
  • FIGURE 30 HUMANIZED MOUSE AND RAT MODEL MARKET: PATENT ANALYSIS, 2014-2024
  • FIGURE 31 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 33 KEY BUYING CRITERIA, BY END USER
  • FIGURE 34 AI USE CASES
  • FIGURE 35 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • FIGURE 36 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT
  • FIGURE 37 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT
  • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2020-2024
  • FIGURE 39 MARKET SHARE ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2024
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 41 COMPANY VALUATION AND FINANCIAL METRICS, 2024
  • FIGURE 42 HUMANIZED MOUSE AND RAT MODEL MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 43 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 44 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY FOOTPRINT
  • FIGURE 45 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 47 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024)
  • FIGURE 48 INOTIV: COMPANY SNAPSHOT (2024)
  • FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 50 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 HARBOUR BIOMED: COMPANY SNAPSHOT (2024)